ABSTRACT
<p><b>INTRODUCTION</b>The aim of this study was to determine the effectiveness of intraocular injections of bevacizumab for neovascularisation of the iris and neovascular glaucoma.</p><p><b>CLINICAL PICTURE</b>Three patients with neovascularisation of the iris due to various causes were recruited.</p><p><b>TREATMENT</b>Patients were treated with intraocular bevacizumab.</p><p><b>OUTCOME</b>Neovascularisation of the iris was noted to have completely regressed as early as 3 days after the injection and in all the patients (100%) within 8 days after injection. They were followed up for at least 1 month with no clinical evidence of recurrence. Visual acuity remained stable or improved, and the intraocular pressure was controlled in all the 3 patients' eyes. Vitreous haemorrhage also cleared. No signs of inflammation or complications were observed.</p><p><b>CONCLUSION</b>Intraocular injection of bevacizumab is effective and safe for patients with neovascularisation of the iris and neovascular glaucoma with or without vitreous haemorrhage.</p>
